BIT
TOVX icon

BlackRock Institutional Trust’s Theriva Biologics TOVX Stock Holding History

BlackRock Institutional Trust’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.4M Buy
210
+5
+2% +$51.3K ﹤0.01% 3180
2016
Q3 		$3.08M Buy
205
+2
+1% +$29.9K ﹤0.01% 2886
2016
Q2 		$3.2M Buy
203
+71
+54% +$1.34M ﹤0.01% 2863
2016
Q1 		$2.73M Hold
132
– – ﹤0.01% 2912
2015
Q4 		$2.65M Hold
132
– – ﹤0.01% 3003
2015
Q3 		$2.63M Buy
132
+67
+103% +$1.65M ﹤0.01% 3015
2015
Q2 		$1.62M Buy
65
+24
+59% +$482K ﹤0.01% 3196
2015
Q1 		$794K Buy
41
+39
+1,950% +$696K ﹤0.01% 3406
2014
Q4 		$30K Buy
+2
New +$26.9K ﹤0.01% 3806

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Institutional Trust's TOVX Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Theriva Biologics (TOVX) stake by 2.4% in Q4 2016, buying an estimated $51.3K and bringing the position to 210 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3180.

BlackRock Institutional Trust first reported a position in TOVX in Q4 2014 and has held it in 9 quarters since. The position peaked at $3.2M in Q2 2016. 70 funds tracked by Wall St. Rank hold TOVX as of Q4 2016.

  • BlackRock Institutional Trust held 210 shares of Theriva Biologics worth $1.4M as of Q4 2016.
  • BlackRock Institutional Trust bought 5 Theriva Biologics shares in Q4 2016, an estimated $51.3K.
  • Theriva Biologics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3180 holding.
  • BlackRock Institutional Trust first reported a position in Theriva Biologics in Q4 2014 and has held it in 9 quarters since.
  • BlackRock Institutional Trust's Theriva Biologics position peaked at $3.2M in Q2 2016.
  • 70 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.